



FDA ADVISORY
No. 2019-051-B

102 JUL 2019

TO: THE GENERAL PUBLIC

SUBJECT: Lifting the Advisory of the following Notified Cosmetic Products under FDA Advisory No. 2019-051 "Public Health Warning Against the Use of Unnotified Cosmetic Products (Batch 2)" Dated 27 February 2019:

1. **ERASE® WHITENING DEODORANT**
2. **GLUTA® BY ERASE WHITENING FACIAL CLEANSER WITH KOREAN GINSENG AND TAWAS**
3. **GLUTA® BY ERASE WHITENING LOTION WITH KOJIC ACID & MORINGA EXTRACT**
4. **GLUTA® BY ERASE WHITENING LOTION WITH KOREAN GINSENG & VITAMIN E**

The Food and Drug Administration (FDA) informs the public that the following cosmetic products have been notified by the Market Authorization Holder (MAH), Jaoming Marketing Corp., in accordance to existing FDA rules and regulations:

1. **Erase® Whitening Deodorant - Notification No. 1000015244320**
2. **Gluta® By Erase Whitening Facial Cleanser with Korean Ginseng and Tawas - Notification No. 1000004397701**
3. **Gluta® By Erase Whitening Lotion with Kojic Acid & Moringa Extract - Notification No. 1000001923286**
4. **Gluta® By Erase Whitening Lotion with Korean Ginseng & Vitamin E - Notification No. 1000002845309**

Accordingly, the list released in FDA Advisory No. 2019-051 is hereby updated to remove the aforementioned cosmetic products.

The public is advised to always check if a cosmetic product is notified with the FDA. The FDA website (www.fda.gov.ph) has a Search feature which may be used by typing in the name of the product before purchasing. Kindly contact the FDA Center for Cosmetics Regulation and Research through e-mail at ccrr@fda.gov.ph, or call **(02) 857-1900 loc. 8113 or 8117**.


To report any sale or distribution of unnotified cosmetic products, the online reporting facility, **eReport** can be accessed at www.fda.gov.ph/ereport.

The public health warning imposed on the remaining products listed in FDA Advisory No. 2019-051 shall remain to be upheld and shall not be affected by the issuance of this advisory.



Furthermore, the issuance of this advisory shall not in any manner preclude this Office from issuing subsequent orders it may deem necessary and appropriate, should there be findings of any violation of the company to the existing laws, rules, and regulations.

Dissemination of this advisory to all concerned is hereby requested.


ROLANDO ENRIQUE D. DOMINGO, MD, DPBO
Undersecretary of Health
Officer-in-Charge, Director General

DTN 20190621164738